Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected investment return exceeding 15% over the next 6-12 months [7]. Core Insights - The company reported a revenue of 210 million yuan for the first half of 2025, representing a year-over-year increase of 9.85%, with a net profit of 69 million yuan, up 39.71% year-over-year [4][5]. - In Q2 2025, the company achieved a revenue of 115 million yuan, reflecting a 10.23% year-over-year growth, and a net profit of 36 million yuan, which is a 29.56% increase year-over-year [5]. - The company's profitability improved significantly due to optimized expense levels, with a decrease in sales, management, and R&D expense ratios [5][6]. Financial Performance - The company's gross margin for Q1 and Q2 of 2025 was approximately 66.65% and 65.62%, respectively, showing recovery compared to Q4 2024 but still lower than Q1 2024 levels [5]. - The company expects revenues of 473 million yuan, 561 million yuan, and 668 million yuan for 2025, 2026, and 2027, respectively, with year-over-year growth rates of 18.2%, 18.6%, and 19.1% [7][9]. - The projected net profits for the same years are 134 million yuan, 160 million yuan, and 192 million yuan, with growth rates of 31.8%, 19.3%, and 20.0% [7][9]. Product Performance - The laser and radiofrequency product lines showed strong growth, with revenues of 21.58 million yuan (up 64.3% year-over-year) and 40.36 million yuan (up 36.2% year-over-year), respectively [6]. - The company launched new products that contributed to revenue growth, including the next-generation VisheeNEO platform, which stabilized the electrical stimulation segment [6]. Future Outlook - The company has introduced a stock incentive plan, projecting revenue growth rates of no less than 18% and 40% for 2025 and 2026, respectively, indicating strong market confidence [6]. - The expected earnings per share (EPS) for 2025, 2026, and 2027 are 1.40 yuan, 1.67 yuan, and 2.01 yuan, with corresponding price-to-earnings (P/E) ratios of 35x, 30x, and 25x [7][9].

公司公告汇总：伟思医疗召开2025年第一次临时股东大会，审议通过取消监事会、修订公司章程 等议案。 公司公告汇总：会议审议通过补选第四届董事会独立董事候选人，并修订部分内部治理制度。 公司公告汇总：出席股东代表股份62,083,029股，占公司有表决权股份总额的64.8646%。 南京伟思医疗科技股份有限公司于2025年9月15日召开2025年第一次临时股东大会，会议由董事会召 集，董事长王志愚主持，采用现场与网络投票相结合方式举行。出席会议的股东及代理人共39人，代表 有表决权股份62,083,029股，占公司有表决权股份总数的64.8646%。 截至2025年9月19日收盘，伟思医疗（688580）报收于49.55元，较上周的50.88元下跌2.61%。本周，伟 思医疗9月18日盘中最高价报52.98元。9月19日盘中最低价报49.24元。伟思医疗当前最新总市值47.45亿 元，在医疗器械板块市值排名78/126，在两市A股市值排名3418/5153。 会议审议通过《关于取消监事会、修订并办理工商变更登记的议案》《关于补选公司第四届董事会独立 董事候选人的议案》及《关于修订部分公司内部治理制度的议案》，所 ...

Core Viewpoint - WeiSi Medical (688580) experienced a decline in stock price, closing at 49.55 yuan on September 19, 2025, down 2.9% from the previous day, with significant net outflows from major funds [1][2]. Financial Performance - The company reported a main revenue of 210 million yuan for the first half of 2025, an increase of 9.85% year-on-year, and a net profit attributable to shareholders of 69.32 million yuan, up 39.71% year-on-year [4]. - The second quarter of 2025 saw a single-quarter main revenue of 115 million yuan, a 10.23% increase year-on-year, and a net profit of 36.10 million yuan, up 29.56% year-on-year [4]. Market Position - WeiSi Medical's total market capitalization is 4.745 billion yuan, with a net asset value of 1.622 billion yuan, and a net profit of 69.32 million yuan, ranking 73rd, 84th, and 46th respectively in the medical device industry [4]. - The company has a price-to-earnings ratio of 34.23 and a price-to-book ratio of 2.93, both of which are favorable compared to the industry averages [4]. Investment Sentiment - Over the past 90 days, six institutions have rated the stock, with five giving a "buy" rating and one an "increase" rating, indicating positive sentiment towards the stock [5]. - The average target price set by institutions for the stock is 60.0 yuan [5]. Fund Flow Analysis - On September 19, 2025, the net inflow of retail funds was 534.96 million yuan, while major funds experienced a net outflow of 517.84 million yuan, indicating a mixed sentiment among different types of investors [1][2]. - The financing balance for WeiSi Medical stood at 216 million yuan, with a net financing purchase of 7.638 million yuan on the same day [2].

证券代码：688580 证券简称：伟思医疗 公告编号：2025-037 南京伟思医疗科技股份有限公司 2025年第一次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 9 月 15 日 （二） 股东大会召开的地点：南京市雨花台区宁双路 19 号 H 栋公司会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 39 | | --- | --- | | 普通股股东人数 | 39 | | 2、出席会议的股东所持有的表决权数量 | 62,083,029 | | 普通股股东所持有表决权数量 | 62,083,029 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比例（%） | 64.8646 | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 64.8646 | 注：截至本次股东大会 ...

伟思医疗 2025年第一次临时股东大会 南京伟思医疗科技股份有限公司: 根据《中华人民共和国公司法》(以下简称"《公司法》")《中华人民共和国 证券法》(以下简称"《证券法》")和中国证监会发布的《上市公司股东会规则》 等法律、法规和规范性文件以及《南京伟思医疗科技股份有限公司章程》(以下 简称"《公司章程》")的规定,本所受公司的委托,指派本所律师出席公司 2025 年第一次临时股东大会,并就本次股东大会的召集、召开程序、出席会议人员资 格、召集人资格、表决程序以及表决结果的合法有效性等事项出具法律意见。 为出具本法律意见书,本所律师对本次股东大会所涉及的有关事项进行了审 查,查阅了相关会议文件,并对有关问题进行了必要的核查和验证。 本所律师同意将本法律意见书随公司本次股东大会决议一并公告,并依法对 本法律意见书承担相应的责任。 本所律师根据相关法律、法规和规范性文件的要求,按照律师行业公认的业 务标准、道德规范和勤勉尽责精神,出具法律意见如下: 一、关于本次股东大会的召集、召开程序 1.本次股东大会的召集 本次股东大会由董事会召集。2025年8月27日,公司召开了第四届董事会 第五次会议,决定于 2025 ...

Core Viewpoint - The company has a strong presence in the non-invasive brain-computer interface (BCI) field, with a comprehensive range of products and technologies, including group biofeedback, multi-parameter biofeedback, and neonatal EEG monitoring [1] Group 1: Product and Technology Development - The company has obtained dozens of patents related to brain-computer interfaces, covering core technologies such as EEG signal acquisition, interference signal correction, signal transmission analysis, and machine learning algorithms [1] - The company has also accumulated multiple patents and technological reserves in non-invasive BCI electrodes [1] Group 2: Neurological Rehabilitation Solutions - The company's technology layout in the neurological rehabilitation field has evolved from a single device to a full-cycle solution encompassing "diagnosis-treatment-rehabilitation" [1] - For closed-loop neurological rehabilitation systems, the company has developed technologies for EEG acquisition, non-invasive neural modulation, and rehabilitation robots, enabling a closed-loop rehabilitation chain that includes brain signal acquisition, intention analysis, magnetic stimulation modulation, and mechanical assistance execution [1] Group 3: Clinical Applications - For stroke patients, the company can capture motor imagery signals in real-time using EEG caps, triggering rehabilitation robots for training while utilizing transcranial magnetic stimulation (TMS) to enhance neural plasticity and accelerate motor function recovery [1] - For spinal cord injury patients, the company's surface electromyography analysis system can assess residual nerve function, combined with a pulsed magnetic field therapy device to intervene in damaged spinal segments, creating personalized rehabilitation plans [1] Group 4: Future Directions - The company will closely monitor the development and application of cutting-edge neuroscience technologies, actively exploring various forms of business and technical cooperation to promote the transition of rehabilitation medicine from traditional models to precision and intelligent development [1]

Core Viewpoint - The company has a strong presence in the non-invasive brain-computer interface (BCI) field, with a comprehensive range of products and technologies, including group biofeedback, multi-parameter biofeedback, and neonatal EEG monitoring [1] Group 1: Product and Technology Development - The company has obtained dozens of patents related to brain-computer interfaces, covering core technologies such as EEG signal acquisition, interference signal correction, signal transmission analysis, and machine learning algorithms [1] - The company has also accumulated multiple patents and technological reserves in non-invasive BCI electrodes [1] Group 2: Neurological Rehabilitation Solutions - The company's technology layout in the neurological rehabilitation field has evolved from a single device to a full-cycle solution encompassing "diagnosis-treatment-rehabilitation" [1] - For closed-loop neurological rehabilitation systems, the company has developed technologies for EEG acquisition, non-invasive neural modulation, and rehabilitation robots, enabling a closed-loop rehabilitation chain that includes brain signal acquisition, intention analysis, magnetic stimulation regulation, and mechanical assistance execution [1] Group 3: Clinical Applications - For stroke patients, the company can capture motor imagery signals in real-time using EEG caps, triggering rehabilitation robots for training while utilizing transcranial magnetic stimulation (TMS) to enhance neural plasticity and accelerate motor function recovery [1] - For spinal cord injury patients, the company's surface electromyography analysis system can assess residual nerve function, combined with a pulsed magnetic field therapy device to intervene in damaged spinal segments, creating personalized rehabilitation plans [1] Group 4: Future Directions - The company will closely monitor the development and application of cutting-edge neuroscience technologies, actively exploring various forms of business and technical cooperation to promote the transition of rehabilitation medicine from traditional models to precision and intelligent development [1]

北信瑞丰健康生活主题灵活配置（001056）基金经理为庞文杰。 资料显示，南京伟思医疗科技股份有限公司位于江苏省南京市雨花台区宁双路19号9栋，成立日期2001 年1月10日，上市日期2020年7月21日，公司主营业务涉及康复医疗器械的研发、生产和销售,以研发创 新为发展驱动力,致力于在盆底及产后康复、神经康复、精神康复等细分领域为医疗及专业机构提供安 全、有效的康复医疗产品及整体解决方案。主营业务收入构成为：磁刺激类39.44%，耗材及配件 19.42%，电生理类19.18%，激光射频类10.26%，电刺激类8.42%，其他3.28%。 从基金十大重仓股角度 数据显示，北信瑞丰基金旗下1只基金重仓伟思医疗。北信瑞丰健康生活主题灵活配置（001056）二季 度减持4万股，持有股数9万股，占基金净值比例为4.68%，位居第七大重仓股。根据测算，今日浮亏损 失约24.3万元。 北信瑞丰健康生活主题灵活配置（001056）成立日期2015年3月27日，最新规模8937.79万。今年以来收 益38.97%，同类排名1228/8179；近一年收益76.4%，同类排名927/7984；成立以来收益32.3%。 9月9日， ...

Group 1 - The core viewpoint of the news is the performance and market position of Weisi Medical, which saw a stock price increase of 5.02% to 54.19 CNY per share, with a total market capitalization of 5.19 billion CNY [1] - Weisi Medical specializes in the research, production, and sales of rehabilitation medical devices, focusing on areas such as pelvic and postpartum rehabilitation, neurological rehabilitation, and mental rehabilitation [1] - The company's revenue composition includes magnetic stimulation products (39.44%), consumables and accessories (19.42%), electrophysiological products (19.18%), laser radiofrequency products (10.26%), electrical stimulation products (8.42%), and others (3.28%) [1] Group 2 - From the perspective of fund holdings, Weisi Medical is a significant investment for the Beixin Ruifeng Health Life Theme Flexible Allocation Fund, which reduced its holdings by 40,000 shares but still holds 90,000 shares, representing 4.68% of the fund's net value [2] - The Beixin Ruifeng Health Life Theme Flexible Allocation Fund has achieved a year-to-date return of 33.09% and a one-year return of 63.27%, ranking 1803 out of 8248 and 1504 out of 8051 in its category, respectively [2] - The fund manager, Pang Wenjie, has a tenure of over 5 years, with the best fund return during this period being 44.46% and the worst being -39.77% [3]

南京伟思医疗科技股份有限公司 2025 年第一次临时股东大会会议资料 证券代码：688580 证券简称：伟思医疗 南京伟思医疗科技股份有限公司 2025年第一次临时股东大会会议资料 2025 年 9 月 南京伟思医疗科技股份有限公司 2025 年第一次临时股东大会会议资料 2025 年第一次临时股东大会会议资料目录 | 2025 年第一次临时股东大会会议资料目录 1 | | | --- | --- | | 2025 年第一次临时股东大会会议须知 1 | | | 2025 年第一次临时股东大会会议议程 4 | | | 议案 1： 6 | | | 《关于取消监事会、修订<公司章程>并办理工商变更登记的议案》 | 6 | | 议案 2： 8 | | | 《关于补选公司第四届董事会独立董事候选人的议案》 | 8 | | 议案 3： 10 | | | 《关于修订部分公司内部治理制度的议案》 | 10 | 南京伟思医疗科技股份有限公司 2025 年第一次临时股东大会会议资料 2025 年第一次临时股东大会会议须知 为了维护全体股东的合法权益，确保股东大会的正常秩序和议事效率，保证 大会的顺利进行，根据《中华人民共和国公司 ...